Applicant, as named in the Orange Book

Arrowhead

Next listed expiry: Redemplo on 10 Sep 2038. 1 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Redemplo plozasiran sodium	plozasiran sodium	219947	10 Sep 2038	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.